Clinical Trial Detail

NCT ID NCT03589469
Title Study to Evaluate the Efficacy and Safety of Loncastuximab Tesirine in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors ADC Therapeutics S.A.
Indications

B-cell lymphoma

diffuse large B-cell lymphoma

Therapies

Loncastuximab tesirine

Age Groups: senior adult

No variant requirements are available.